Instadose Competitors

INSD Stock  USD 0  0.00  0.00%   
Instadose Pharma Corp competes with Emergent Biosolutions, Collegium Pharmaceutical, Intracellular, and Durect; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Instadose Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Instadose Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Instadose Pharma Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Instadose Pharma competition on your existing holdings.
  
At present, Instadose Pharma's Return On Equity is projected to increase slightly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 623.27, whereas Net Tangible Assets are projected to grow to (138.8 K).
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Instadose Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.0000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.00090.00
Details

Instadose Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Instadose Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Instadose and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Instadose Pharma Corp does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
COLLEBS
ITCICOLL
DRRXEBS
DRRXCOLL
DCPHEBS
DCPHCOLL
  
High negative correlations   
DRRXITCI
ITCIEBS
DRRXDCPH
ITCIDCPH
DCPHCOLL
DCPHEBS

Risk-Adjusted Indicators

There is a big difference between Instadose Stock performing well and Instadose Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Instadose Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Instadose Pharma Corp and related stocks such as Emergent Biosolutions, Collegium Pharmaceutical, and Deciphera Pharmaceuticals Net Income Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareRoic
Inventory TurnoverNet Income Per Share
Days Of Inventory On HandPayables Turnover
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityRoe
Tangible Asset ValueEv To Operating Cash Flow
Pe RatioReturn On Tangible Assets
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D ADividend Yield
Earnings YieldShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
EBS(554 K)23 M23.5 M31.1 M36.7 M62.9 M51.8 M82.6 M62.7 M54.5 M305.8 M219.5 M(223.8 M)(760.5 M)(190.6 M)(181.1 M)
COLL(16.2 M)(16.2 M)(16.2 M)(16.2 M)(17.9 M)(27.3 M)(94.2 M)(74.9 M)(39.1 M)(8.1 M)26.8 M71.5 M(25 M)48.2 M69.2 M72.6 M
ITCI11.1 M11.1 M(16.6 M)(26.9 M)(30.7 M)(104.8 M)(116.4 M)(97.8 M)(155.1 M)(147.7 M)(227 M)(284.1 M)(256.3 M)(139.7 M)(74.7 M)(78.4 M)
DRRX(8.7 M)(18.8 M)16.2 M(21.5 M)(22.1 M)(22.7 M)(34.5 M)(3.7 M)(25.3 M)(22.8 M)(2.5 M)(38.1 M)(35.6 M)(27.6 M)(31.8 M)(33.4 M)

Instadose Pharma Corp and related stocks such as Emergent Biosolutions, Collegium Pharmaceutical, and Deciphera Pharmaceuticals Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Instadose Pharma Corp financial statement analysis. It represents the amount of money remaining after all of Instadose Pharma Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Instadose Pharma Competitive Analysis

The better you understand Instadose Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Instadose Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Instadose Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
INSD EBS COLL ITCI DRRX
 0.00 
 0 
Instadose
 3.63 
 5.71 
Emergent
 1.24 
 29.46 
Collegium
 0.08 
 131.26 
Intracellular
 6.17 
 0.86 
Durect
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Current Valuation
Price To Book
Operating Margin
Retained Earnings
Current Asset
One Year Return
Beta
Equity Positions Weight
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Total Debt
Return On Equity
Return On Asset
Book Value Per Share
Number Of Shares Shorted
Current Liabilities
Total Asset
Debt To Equity
Short Ratio
Target Price
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Year To Date Return
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Instadose Pharma Competition Performance Charts

Five steps to successful analysis of Instadose Pharma Competition

Instadose Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Instadose Pharma Corp in relation to its competition. Instadose Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Instadose Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Instadose Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Instadose Pharma Corp, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Instadose Pharma position

In addition to having Instadose Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small & Mid Caps ETFs Thematic Idea Now

Small & Mid Caps ETFs
Small & Mid Caps ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Instadose Pharma Corp is a strong investment it is important to analyze Instadose Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instadose Pharma's future performance. For an informed investment choice regarding Instadose Stock, refer to the following important reports:
Check out Instadose Pharma Correlation with its peers.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instadose Pharma. If investors know Instadose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instadose Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(694.06)
The market value of Instadose Pharma Corp is measured differently than its book value, which is the value of Instadose that is recorded on the company's balance sheet. Investors also form their own opinion of Instadose Pharma's value that differs from its market value or its book value, called intrinsic value, which is Instadose Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instadose Pharma's market value can be influenced by many factors that don't directly affect Instadose Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instadose Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instadose Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instadose Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.